Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Healthcare Stakeholders Weigh Fallout after Ruling Bloc’s Election Setback
Lawmakers and pharmaceutical industry voices are taking stock of Japan’s shifting political landscape following the ruling camp’s defeat in the July 20 Upper House election, as they brace for policy implications ahead of the FY2026 reimbursement reform. The Liberal Democratic…
To read the full story
Related Article
- Pharmaceutical Policy at a Crossroad amid Political Upheaval in Japan
July 28, 2025
- Japan’s Ruling Bloc Routed in Upper House Poll; Takemi to Retire, Furukawa, Kamayachi, and Honda Secure Seats
July 22, 2025
- Japan’s Major Parties Outline Various Drug Policy Visions Ahead of Upper House Poll
July 14, 2025
- Healthcare-Linked Candidates Launch Campaigns as Upper House Election Gets Underway
July 4, 2025
- Upper House Campaign Begins in Japan, Healthcare and Pharma-Linked Candidates in Spotlight
July 3, 2025
- Ex-Health Minister Takemi Vows to Bolster Japan’s Drug Development and Supply Resilience
July 2, 2025
- LDP’s Honda Pledges Strong Support for Pharma Sector via Pro-Innovation Pricing and Supply Stabilization
July 2, 2025
- LDP’s Furukawa Vows Policy Support for Domestic Innovation in New Modalities
June 30, 2025
- DPP’s Tamura Renews Call to Scrap Off-Year Drug Price Cuts, Urges Protection of On-Patent Prices
June 26, 2025
- JMA’s Upper House Candidate Says Scraping Drug Prices to Pool Resources No Longer Holds
June 17, 2025
REGULATORY
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
- Health Insurance Reform Bill Sails Through Lower House
April 30, 2026
- MOF Pushes for Full-Scale FY2027 Off-Year Drug Price Revision Ahead of “Spring” Proposal
April 28, 2026
- Japan Panel Backs Boehringer’s IPF Drug, Moderna COVID Vaccine
April 28, 2026
- Japan Allows Flexibility on Pharmacopoeia Test Differences in Supply Crunch
April 28, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…